ReNeuron’s interim results highlight the positive progress of its stem cell therapy candidates. Positive long term data from a Phase II trial (PISCES II) evaluating CTX stem cell therapy candidate for stroke was announced in October and an IND has been approved (announced this morning) to commence a Phase IIb (PISCES III) trial. It is still expected to start in H1 2018 with data in late 2019. The Phase I element of the ongoing Phase I/II trial evaluating the group’s hRPC stem cell therapy in ret ....
14 Dec 2017
N+1 Singer - ReNeuron Group - Interim results and IND approved to commence Phase IIb in stroke
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Interim results and IND approved to commence Phase IIb in stroke
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
14 Dec 2017 -
Author:
Sheena Berry -
Pages:
4
ReNeuron’s interim results highlight the positive progress of its stem cell therapy candidates. Positive long term data from a Phase II trial (PISCES II) evaluating CTX stem cell therapy candidate for stroke was announced in October and an IND has been approved (announced this morning) to commence a Phase IIb (PISCES III) trial. It is still expected to start in H1 2018 with data in late 2019. The Phase I element of the ongoing Phase I/II trial evaluating the group’s hRPC stem cell therapy in ret ....